Sanja Selak of Intercell AG, Vienna, Austria, presents at the ProImmune Antigen Characterization and Biomarker Discovery Summit, January 2011.
Intercell develops vaccines for the prevention and treatment of infectious diseases
ProImmune Antigen Characterization Summit Paul Mossamandacturner
This document summarizes research on the immune response to cytomegalovirus (CMV) and cancer-testis antigens (CTAgs). It discusses how CMV elicits a massive immune response, occupying up to 40% of CD8+ T cells. This response declines with immunosuppression. It also explores using CMV-specific T cells for immunotherapy after stem cell transplantation. The document then examines CTAgs, which are expressed in cancers and elicit anti-tumor immune responses, but challenges remain in understanding their efficacy.
ProImmune Antigen Characterization Summit Johanna Olweusamandacturner
Johanna Olweus, Dept Immunology, Institute for Cancer Research, Radiumshospitalet, Oslo, Norway, presents at the ProImmune Antigen Characterization and Biomarker Discovery Summit, January 2011.
Cancer immunotherapy: finding allies among the "allos"
This document discusses challenges and opportunities for developing an AIDS vaccine. It describes several key difficulties, including HIV's sequence diversity, ability to infect immune cells, and mechanisms for immune avoidance. The document also reviews past vaccine trial results and discusses various vaccine design approaches, including those aimed at eliciting cytotoxic T-lymphocytes, antibodies, or using viral vectors. Developing an effective AIDS vaccine will likely require a multi-disciplinary approach and stimulation of multiple arms of the immune system.
Protein biomarker capabilities for NanosphereWinton Gibbons
The document discusses protein biomarker detection capabilities using nanoparticle probes. It describes a range of protein biomarker concentrations that can be detected, from millimolar to zeptomolar, and examples of disease areas like cancer, Alzheimer's, and cardiovascular disease. It also outlines opportunities for protein biomarker tests in areas like autoimmune disease, pharmacogenomics, respiratory infections, and cardiac biomarkers. The technology uses gold nanoparticle probes attached to capture antibodies to detect proteins through light scattering techniques.
USP CHOP Annie De Groot Presentation June 2013Business EpiVax
This document discusses residual host cell proteins (HCPs) in therapeutic protein formulations and their potential impact on immunogenicity. It provides several examples showing how minor mismatches between species sequences can lead to an immune response. The key points are that T cell epitopes drive immunogenicity, and proteins that are normally self-tolerated can become immunogenic if they contain T cell epitopes foreign to the patient. HCPs from CHO cell lines used in production may contain such non-self epitopes and have canceled clinical trials due to unexpected immune responses against CHO components. A thorough immunoinformatics analysis of contaminating proteins is important to understand and mitigate immunogenicity risks.
1) Malaria vaccines aim to prevent infection, decrease disease severity, and reduce transmission. However, developing an effective malaria vaccine is challenging due to the parasite's high mutation rate and ability to evade the immune system.
2) Most research focuses on P. falciparum since it causes the most mortality. Potential vaccine candidates target different stages of the parasite's life cycle and include antigens like CSP, AMA1, MSP1, and Pfs25.
3) SPf66 was the first malaria vaccine tested in humans but showed limited efficacy. RTS,S is the most advanced candidate vaccine and has demonstrated up to 50% efficacy in clinical trials. However, more research is still needed to develop
Presentation by adrian hill [university of oxford]Pamoja
Malaria is a major global health problem, killing over 700,000 people annually. Developing an effective vaccine is challenging due to the parasite's complex life cycle and ability to evade the immune system. Current vaccine approaches include protein-adjuvant vaccines targeting specific stages, viral vectored vaccines to induce cellular immunity, and whole parasite vaccines. Significant progress has been made, but partial efficacy has required unprecedented immunogenicity. A multi-component vaccine targeting multiple stages may be needed for high efficacy.
The document describes malaria immunology and epidemiology studies conducted in Papua New Guinea between 2004-2017. It involved several cohort and intervention studies with observational cohorts of approximately 500-2000 individuals. The studies aimed to understand immunity targets and mechanisms to malaria in order to rationalize vaccine development. They examined both antibody and cellular immune responses. Key findings included that γδ T cells are a major source of IFNγ response and certain NK cell receptors are associated with risk of high density infections.
ProImmune Antigen Characterization Summit Paul Mossamandacturner
This document summarizes research on the immune response to cytomegalovirus (CMV) and cancer-testis antigens (CTAgs). It discusses how CMV elicits a massive immune response, occupying up to 40% of CD8+ T cells. This response declines with immunosuppression. It also explores using CMV-specific T cells for immunotherapy after stem cell transplantation. The document then examines CTAgs, which are expressed in cancers and elicit anti-tumor immune responses, but challenges remain in understanding their efficacy.
ProImmune Antigen Characterization Summit Johanna Olweusamandacturner
Johanna Olweus, Dept Immunology, Institute for Cancer Research, Radiumshospitalet, Oslo, Norway, presents at the ProImmune Antigen Characterization and Biomarker Discovery Summit, January 2011.
Cancer immunotherapy: finding allies among the "allos"
This document discusses challenges and opportunities for developing an AIDS vaccine. It describes several key difficulties, including HIV's sequence diversity, ability to infect immune cells, and mechanisms for immune avoidance. The document also reviews past vaccine trial results and discusses various vaccine design approaches, including those aimed at eliciting cytotoxic T-lymphocytes, antibodies, or using viral vectors. Developing an effective AIDS vaccine will likely require a multi-disciplinary approach and stimulation of multiple arms of the immune system.
Protein biomarker capabilities for NanosphereWinton Gibbons
The document discusses protein biomarker detection capabilities using nanoparticle probes. It describes a range of protein biomarker concentrations that can be detected, from millimolar to zeptomolar, and examples of disease areas like cancer, Alzheimer's, and cardiovascular disease. It also outlines opportunities for protein biomarker tests in areas like autoimmune disease, pharmacogenomics, respiratory infections, and cardiac biomarkers. The technology uses gold nanoparticle probes attached to capture antibodies to detect proteins through light scattering techniques.
USP CHOP Annie De Groot Presentation June 2013Business EpiVax
This document discusses residual host cell proteins (HCPs) in therapeutic protein formulations and their potential impact on immunogenicity. It provides several examples showing how minor mismatches between species sequences can lead to an immune response. The key points are that T cell epitopes drive immunogenicity, and proteins that are normally self-tolerated can become immunogenic if they contain T cell epitopes foreign to the patient. HCPs from CHO cell lines used in production may contain such non-self epitopes and have canceled clinical trials due to unexpected immune responses against CHO components. A thorough immunoinformatics analysis of contaminating proteins is important to understand and mitigate immunogenicity risks.
1) Malaria vaccines aim to prevent infection, decrease disease severity, and reduce transmission. However, developing an effective malaria vaccine is challenging due to the parasite's high mutation rate and ability to evade the immune system.
2) Most research focuses on P. falciparum since it causes the most mortality. Potential vaccine candidates target different stages of the parasite's life cycle and include antigens like CSP, AMA1, MSP1, and Pfs25.
3) SPf66 was the first malaria vaccine tested in humans but showed limited efficacy. RTS,S is the most advanced candidate vaccine and has demonstrated up to 50% efficacy in clinical trials. However, more research is still needed to develop
Presentation by adrian hill [university of oxford]Pamoja
Malaria is a major global health problem, killing over 700,000 people annually. Developing an effective vaccine is challenging due to the parasite's complex life cycle and ability to evade the immune system. Current vaccine approaches include protein-adjuvant vaccines targeting specific stages, viral vectored vaccines to induce cellular immunity, and whole parasite vaccines. Significant progress has been made, but partial efficacy has required unprecedented immunogenicity. A multi-component vaccine targeting multiple stages may be needed for high efficacy.
The document describes malaria immunology and epidemiology studies conducted in Papua New Guinea between 2004-2017. It involved several cohort and intervention studies with observational cohorts of approximately 500-2000 individuals. The studies aimed to understand immunity targets and mechanisms to malaria in order to rationalize vaccine development. They examined both antibody and cellular immune responses. Key findings included that γδ T cells are a major source of IFNγ response and certain NK cell receptors are associated with risk of high density infections.
Washington Global Health Alliance Discovery Series
Robert Sinden, PhD
July 28, 2008
'Understanding Malaria Development in the Mosquito, and its Pivotal Role in the Formulation of Effective Control Strategies'
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
This document summarizes information about malaria vaccines. It discusses how malaria is caused by Plasmodium parasites and transmitted by mosquitoes. Four species can infect humans. Current vaccines target different stages of the parasite's life cycle, including pre-erythrocytic, blood, and sexual stages. Challenges to vaccine development include the parasite's ability to evade the immune system through antigenic variation. Several candidate vaccines are discussed that target different stages, but none have achieved high levels of efficacy and durability.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le terrain ? - Conférence de la 8e édition du Cours international « Atelier Paludisme » - RAZAKANDRAINIBE Romy - Madagascar - romy@pasteur.mg
T-cell responses induced by an Ad35-vectored HIV vaccine were broad, durable, polyfunctional and could inhibit HIV in a phase I trial. The vaccine induced HIV-specific T-cell responses in over 86% of subjects as measured by IFN-γ ELISPOT. Responses targeted multiple HIV proteins and were predominantly from CD8+ T-cells. T-cells exhibited multifunctionality with cytokine production and degranulation. Modest antibody responses were induced with no neutralizing antibodies detected. Further studies will evaluate prime-boost regimens to enhance the breadth and potency of immune responses.
Dr. Ben Hause - Metagenomic Sequencing for Virus Discovery and CharacterizationJohn Blue
Metagenomic Sequencing for Virus Discovery and Characterization - Dr. Ben Hause, Kansas State University, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Dr. Ben Hause - Pathogen Discovery Using Metagenomic SequencingJohn Blue
Pathogen Discovery Using Metagenomic Sequencing - Dr. Ben Hause, College of Veterinary Medicine, Kansas State University, from the 2016 Allen D. Leman Swine Conference, September 17-20, 2016, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2016-leman-swine-conference-material
This document discusses the diagnosis and genetic testing of primary immunodeficiencies. It begins by defining primary immunodeficiency as congenital or hereditary defects of the immune system resulting in increased infections. It then classifies primary immunodeficiencies and lists the most common infectious agents seen. The document goes on to discuss specific genetic mutations that can cause various forms of severe combined immunodeficiency (SCID) or other primary immunodeficiencies. Case studies are presented to illustrate the genetic testing process and diagnosis of conditions like perforin deficiency.
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
This slide is about the basics of mRNA-based therapy. The content includes: definition of mRNA, timeline of mRNA therapeutics, action mechanism and development strategies of mRNA drugs, therapeutic mRNA applications, and the related services provided by Creative Biolabs.
In Vitro Diagnostic (IVD) Antibody Development - Creative BiolabsCreative-Biolabs
This slide is a brief introduction of in vitro diagnostic (IVD) antibody development. This presentation includes the introduction of background, principle and process of antibody development, difficulties in antibody development, as well as the antibody services of Creative Biolabs.
This document provides information about malaria vaccines. It discusses the context of malaria globally and the need for a vaccine. Several potential vaccine candidates target different stages of the malaria parasite's lifecycle, including sporozoites, infected hepatocytes, and erythrocytic stages. Developing an effective vaccine is challenging due to the parasite's diversity and complexity. The most promising current candidate is RTS,S, which provides some protection against malaria in clinical trials but is not fully effective.
project of Advanced Gene & Cell Technologies Ltd. (AGCT) - Skolkovo startup: Cell gene therapy of HIV-associated malignancies and HIV based on hematopoietic stem cell transplantation and site-specific genome editing
This document discusses a thesis presented by Priyanka Rughwani to the USC Graduate School examining factors that contribute to outcomes of Staphylococcus aureus bacteremia. The introduction provides background on the increasing incidence of S. aureus infections including methicillin-resistant S. aureus. It describes how S. aureus has developed resistance to multiple antibiotic classes and discusses the role of virulence factors and their impact on infection outcomes. The study aims to analyze the contribution of microbial resistance and virulence factors like agr functionality, protein A, and extracellular adherence protein towards persistent SAB or death.
This document discusses autoantibodies known as antinuclear antibodies (ANA) that are directed against nuclear antigens. It covers the prevalence of ANA, various nuclear antigens they may be directed against like DNA and histones, mechanisms of autoimmunity and autoantibody production, roles of B cells and T cells, and methods of detecting ANAs. It also describes different patterns of ANA fluorescence and their associations with various autoimmune diseases.
Monoclonal antibody, history, development and progressRadhika Hegde
Monoclonal antibodies (mAbs) are artificially produced antibodies that are all identical and recognize the same epitope. This document summarizes the history and production of mAbs, from early discoveries in the late 19th century to modern techniques. It describes the key breakthrough of hybridoma technology by Köhler and Milstein in 1975 that allowed mass production of mAbs by fusing antibody-producing cells with myeloma cells. Various approaches to mAb production are also summarized, including recombinant techniques, phage display, plantibodies, bacterial display, and yeast display. The document concludes with discussion of applications, clinical trials, and future innovations using mAb technology.
This document provides an overview of edible vaccines. It discusses how edible vaccines are produced by introducing genes encoding vaccine antigens into edible plants using transformation methods. The document outlines various plant species used for edible vaccines like tomatoes, rice, maize, potatoes, and tobacco. It discusses factors affecting the efficacy of edible vaccines and provides examples of edible vaccine research for diseases like malaria, measles, hepatitis B, norovirus, and Alzheimer's disease. The conclusion states that edible vaccines could improve vaccination programs in developing countries by reducing costs and need for cold storage.
Washington Global Health Alliance Discovery Series
Robert Sinden, PhD
July 28, 2008
'Understanding Malaria Development in the Mosquito, and its Pivotal Role in the Formulation of Effective Control Strategies'
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
This document summarizes information about malaria vaccines. It discusses how malaria is caused by Plasmodium parasites and transmitted by mosquitoes. Four species can infect humans. Current vaccines target different stages of the parasite's life cycle, including pre-erythrocytic, blood, and sexual stages. Challenges to vaccine development include the parasite's ability to evade the immune system through antigenic variation. Several candidate vaccines are discussed that target different stages, but none have achieved high levels of efficacy and durability.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le terrain ? - Conférence de la 8e édition du Cours international « Atelier Paludisme » - RAZAKANDRAINIBE Romy - Madagascar - romy@pasteur.mg
T-cell responses induced by an Ad35-vectored HIV vaccine were broad, durable, polyfunctional and could inhibit HIV in a phase I trial. The vaccine induced HIV-specific T-cell responses in over 86% of subjects as measured by IFN-γ ELISPOT. Responses targeted multiple HIV proteins and were predominantly from CD8+ T-cells. T-cells exhibited multifunctionality with cytokine production and degranulation. Modest antibody responses were induced with no neutralizing antibodies detected. Further studies will evaluate prime-boost regimens to enhance the breadth and potency of immune responses.
Dr. Ben Hause - Metagenomic Sequencing for Virus Discovery and CharacterizationJohn Blue
Metagenomic Sequencing for Virus Discovery and Characterization - Dr. Ben Hause, Kansas State University, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Dr. Ben Hause - Pathogen Discovery Using Metagenomic SequencingJohn Blue
Pathogen Discovery Using Metagenomic Sequencing - Dr. Ben Hause, College of Veterinary Medicine, Kansas State University, from the 2016 Allen D. Leman Swine Conference, September 17-20, 2016, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2016-leman-swine-conference-material
This document discusses the diagnosis and genetic testing of primary immunodeficiencies. It begins by defining primary immunodeficiency as congenital or hereditary defects of the immune system resulting in increased infections. It then classifies primary immunodeficiencies and lists the most common infectious agents seen. The document goes on to discuss specific genetic mutations that can cause various forms of severe combined immunodeficiency (SCID) or other primary immunodeficiencies. Case studies are presented to illustrate the genetic testing process and diagnosis of conditions like perforin deficiency.
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
This slide is about the basics of mRNA-based therapy. The content includes: definition of mRNA, timeline of mRNA therapeutics, action mechanism and development strategies of mRNA drugs, therapeutic mRNA applications, and the related services provided by Creative Biolabs.
In Vitro Diagnostic (IVD) Antibody Development - Creative BiolabsCreative-Biolabs
This slide is a brief introduction of in vitro diagnostic (IVD) antibody development. This presentation includes the introduction of background, principle and process of antibody development, difficulties in antibody development, as well as the antibody services of Creative Biolabs.
This document provides information about malaria vaccines. It discusses the context of malaria globally and the need for a vaccine. Several potential vaccine candidates target different stages of the malaria parasite's lifecycle, including sporozoites, infected hepatocytes, and erythrocytic stages. Developing an effective vaccine is challenging due to the parasite's diversity and complexity. The most promising current candidate is RTS,S, which provides some protection against malaria in clinical trials but is not fully effective.
project of Advanced Gene & Cell Technologies Ltd. (AGCT) - Skolkovo startup: Cell gene therapy of HIV-associated malignancies and HIV based on hematopoietic stem cell transplantation and site-specific genome editing
This document discusses a thesis presented by Priyanka Rughwani to the USC Graduate School examining factors that contribute to outcomes of Staphylococcus aureus bacteremia. The introduction provides background on the increasing incidence of S. aureus infections including methicillin-resistant S. aureus. It describes how S. aureus has developed resistance to multiple antibiotic classes and discusses the role of virulence factors and their impact on infection outcomes. The study aims to analyze the contribution of microbial resistance and virulence factors like agr functionality, protein A, and extracellular adherence protein towards persistent SAB or death.
This document discusses autoantibodies known as antinuclear antibodies (ANA) that are directed against nuclear antigens. It covers the prevalence of ANA, various nuclear antigens they may be directed against like DNA and histones, mechanisms of autoimmunity and autoantibody production, roles of B cells and T cells, and methods of detecting ANAs. It also describes different patterns of ANA fluorescence and their associations with various autoimmune diseases.
Monoclonal antibody, history, development and progressRadhika Hegde
Monoclonal antibodies (mAbs) are artificially produced antibodies that are all identical and recognize the same epitope. This document summarizes the history and production of mAbs, from early discoveries in the late 19th century to modern techniques. It describes the key breakthrough of hybridoma technology by Köhler and Milstein in 1975 that allowed mass production of mAbs by fusing antibody-producing cells with myeloma cells. Various approaches to mAb production are also summarized, including recombinant techniques, phage display, plantibodies, bacterial display, and yeast display. The document concludes with discussion of applications, clinical trials, and future innovations using mAb technology.
This document provides an overview of edible vaccines. It discusses how edible vaccines are produced by introducing genes encoding vaccine antigens into edible plants using transformation methods. The document outlines various plant species used for edible vaccines like tomatoes, rice, maize, potatoes, and tobacco. It discusses factors affecting the efficacy of edible vaccines and provides examples of edible vaccine research for diseases like malaria, measles, hepatitis B, norovirus, and Alzheimer's disease. The conclusion states that edible vaccines could improve vaccination programs in developing countries by reducing costs and need for cold storage.
The document summarizes the development of three types of LAB-based (lactic acid bacteria-based) vaccines described in a Ph.D. thesis. It describes (1) the development of a safer plasmid DNA vaccine using L. lactis that obtained comparable antibody responses to an E. coli vector but lower CD8+ T cell activation, (2) the production of the peanut allergen Ara h 2 in L. lactis and its authenticity, and (3) the use of LAB for antigen delivery by presenting antigens on their surface and through adhesion mechanisms aided by molecules like the mannose-binding adhesin.
Gene Olinger, USAMRIID, Fort Detrick USA, presents at the ProImmune Antigen Characterization and Biomarker Discovery Summit, January 2011.
Protective Immune Reponses to Ebola Virus
La disponibilidad de un sistema de multiplicación del virus de la hepatitis C (VHC) infeccioso en cultivos celulares está permitiendo investigar nuevos factores de respuesta a tratamientos antivíricos en condiciones controladas. Se presentará evidencia de que el fitness vírico puede ser un factor de multiresistencia a inhibidores y quese pueden obtener eficientes reducciones de carga viral empleando diseños secuenciales de administración de inhibidores que incluyan ribavirina. Se discutirán posibilidades de aplicación clínica.
This document summarizes immune evasion strategies used by flaviviruses. It discusses how flaviviruses evade innate immune responses such as type I interferon responses and complement system activation. It also describes adaptive immune evasion mechanisms, including antigenic variation, antibody-dependent enhancement of infection, and inhibition of antigen presentation. The document provides diagrams illustrating key concepts and cites related studies on flavivirus immune evasion and modulation of host inflammatory responses.
This presentation discusses novel technologies to study the resistome, which is the collection of antibiotic resistance genes found in an environment. It describes culture-based and culture-independent methods to analyze the resistome, including metagenomic shotgun sequencing, functional metagenomics, and high-throughput quantitative PCR. The presentation also details a study that used these methods to analyze the gut resistome of ICU patients receiving intensive antibiotic therapy and found a rich diversity of resistance genes that increased during their hospital stay. Long-read nanopore sequencing is also presented as an upcoming method to map resistomes by linking resistance genes to mobile genetic elements.
recent development in culture od CestodeAbdullah Jan
The document discusses recent developments in culturing cestode parasites. It is a complex process due to the parasites' life cycles involving different host species. Researchers have developed vaccines using cultured parasite antigens to prevent infections in livestock. Cultured parasites have also been used to identify diagnostic components, screen drugs, study cell growth and differentiation, and examine phylogenetic relationships. Maintaining cestode cultures has aided the cloning and sequencing of oncosphere genes.
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
1) A peptide library-based workflow was developed to address the challenge of sequence diversity in immunotherapy development. This combines improved bioinformatics algorithms, high-throughput peptide synthesis, and innovative peptide presentation approaches.
2) The bioinformatics algorithms select peptides that provide the most homogenous coverage of known sequences, reducing the number of peptides needed. Overlapping peptide pools are also used.
3) Peptide microarrays are used to study humoral immunity against diverse sequences, while peptide pools presented in various ways study cellular immunity.
4) Examples showed the approach identified correlates of protection in vaccine studies and expanded HIV-specific T cells for therapy.
The 'omics' revolution: How will it improve our understanding of infections a...WAidid
This slideset explains the ‘Omics’ technology and its role in the study of infections and vaccination. It is a revolution as it offers powerful tools to interrogate the animal / human immune response to vaccines and infections.
This document outlines Patient Safety Goal 4 to tackle antimicrobial resistance as part of WHO's 3rd Global Patient Safety Challenge. It describes 3 indicators to monitor the incidence of MRSA, ESBL-Klebsiella Pneumoniae, and ESBL-E.coli infections. Data on newly identified multidrug resistant organism cases will be collected and the infection rates calculated monthly. Strategies like implementing antibiotic guidelines, stewardship programs, and national campaigns aim to optimize antibiotic use and contain the spread of antimicrobial resistance.
Identification of antibiotic resistance genes in Klebsiella pneumoniae isolat...QIAGEN
This document describes a study that developed and validated a real-time PCR array to identify 87 antibiotic resistance genes from bacterial isolates and metagenomic samples. The array was used to profile resistance genes in Klebsiella pneumoniae isolates and human stool samples. A variety of resistance genes were detected, including SHV, KPC, ermB, mefA and tetA. The PCR array results were confirmed using pyrosequencing and shown to be effective for monitoring the spread of antibiotic resistance.
Vaccines are valuable and specialized products, of great diversity have already achieved great success in controlling many diseases of economics importance in farm and companion animals, but present they do not cover all infections, access to modern techniques are used for designing to new vaccine ,not only prolongation of immunity, but also to better practical aspects, such as product stability and less dependence on cold-storage.
This study analyzed blood cultures from neonatal intensive care unit patients from 1997 to 2001 in Tripoli Medical Center, Libya. A total of 1431 blood culture sets from 1092 patients were positive for bacterial growth in 801 sets, representing 648 cases of neonatal bacteraemia. The most common causative agents were members of the Enterobacteriaceae family including Serratia, Klebsiella, and Enterobacter species as well as coagulase-negative and positive Staphylococci. Antibiotic susceptibility testing found high levels of resistance among the most frequent pathogens, though resistance to newer antibiotics like aztreonam and imipenem was less common. Resistance in Staphylococcus to anti-stap
Presented by Vish Nene at the Workshop on the Distribution, Delivery and Improvement of the
Infection and Treatment Method Vaccine for East Coast Fever, Nairobi, 19-20 August 2014
Production and applications of monoclonal antibodiesKaayathri Devi
production and applications of monoclonal antibodies, monoclonal antibodies ,applications of monoclonal antibodies, production of monoclonal antibodies,
SEROLOGICAL METHODS FOR DETECTION OF PLANT PATHOGENSHARISH J
This document discusses serological methods for detecting plant pathogens. It explains that serodiagnosis involves inducing an immune response in an animal to produce antibodies against a pathogen's antigens. These antibodies can then be used to detect the presence of the pathogen. The document describes several serological testing methods including ring interface tests, microprecipitin tests, double diffusion tests, ELISA, immunosorbent electron microscopy, and immunofluorescent staining. It concludes that serodiagnosis is a sensitive tool for identifying pathogens, detecting infections, and quantifying crop diseases.
This document discusses molecular epidemiology techniques for tracing bacterial pathogens. It begins by introducing conventional typing methods like biotyping and antimicrobial susceptibility testing. It then describes key DNA-based techniques including restriction fragment length polymorphism (RFLP) analysis, Southern blotting, pulsed-field gel electrophoresis (PFGE), and PCR-based methods. Examples are provided where these techniques were used to trace the source of antimicrobial-resistant Salmonella infections and characterize Mycobacterium tuberculosis transmission patterns in San Francisco.
Similar to ProImmune Antigen Characterization Summit Sanja Selak (20)
Building RAG with self-deployed Milvus vector database and Snowpark Container...Zilliz
This talk will give hands-on advice on building RAG applications with an open-source Milvus database deployed as a docker container. We will also introduce the integration of Milvus with Snowpark Container Services.
Full-RAG: A modern architecture for hyper-personalizationZilliz
Mike Del Balso, CEO & Co-Founder at Tecton, presents "Full RAG," a novel approach to AI recommendation systems, aiming to push beyond the limitations of traditional models through a deep integration of contextual insights and real-time data, leveraging the Retrieval-Augmented Generation architecture. This talk will outline Full RAG's potential to significantly enhance personalization, address engineering challenges such as data management and model training, and introduce data enrichment with reranking as a key solution. Attendees will gain crucial insights into the importance of hyperpersonalization in AI, the capabilities of Full RAG for advanced personalization, and strategies for managing complex data integrations for deploying cutting-edge AI solutions.
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
In his public lecture, Christian Timmerer provides insights into the fascinating history of video streaming, starting from its humble beginnings before YouTube to the groundbreaking technologies that now dominate platforms like Netflix and ORF ON. Timmerer also presents provocative contributions of his own that have significantly influenced the industry. He concludes by looking at future challenges and invites the audience to join in a discussion.
In the rapidly evolving landscape of technologies, XML continues to play a vital role in structuring, storing, and transporting data across diverse systems. The recent advancements in artificial intelligence (AI) present new methodologies for enhancing XML development workflows, introducing efficiency, automation, and intelligent capabilities. This presentation will outline the scope and perspective of utilizing AI in XML development. The potential benefits and the possible pitfalls will be highlighted, providing a balanced view of the subject.
We will explore the capabilities of AI in understanding XML markup languages and autonomously creating structured XML content. Additionally, we will examine the capacity of AI to enrich plain text with appropriate XML markup. Practical examples and methodological guidelines will be provided to elucidate how AI can be effectively prompted to interpret and generate accurate XML markup.
Further emphasis will be placed on the role of AI in developing XSLT, or schemas such as XSD and Schematron. We will address the techniques and strategies adopted to create prompts for generating code, explaining code, or refactoring the code, and the results achieved.
The discussion will extend to how AI can be used to transform XML content. In particular, the focus will be on the use of AI XPath extension functions in XSLT, Schematron, Schematron Quick Fixes, or for XML content refactoring.
The presentation aims to deliver a comprehensive overview of AI usage in XML development, providing attendees with the necessary knowledge to make informed decisions. Whether you’re at the early stages of adopting AI or considering integrating it in advanced XML development, this presentation will cover all levels of expertise.
By highlighting the potential advantages and challenges of integrating AI with XML development tools and languages, the presentation seeks to inspire thoughtful conversation around the future of XML development. We’ll not only delve into the technical aspects of AI-powered XML development but also discuss practical implications and possible future directions.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Sudheer Mechineni, Head of Application Frameworks, Standard Chartered Bank
Discover how Standard Chartered Bank harnessed the power of Neo4j to transform complex data access challenges into a dynamic, scalable graph database solution. This keynote will cover their journey from initial adoption to deploying a fully automated, enterprise-grade causal cluster, highlighting key strategies for modelling organisational changes and ensuring robust disaster recovery. Learn how these innovations have not only enhanced Standard Chartered Bank’s data infrastructure but also positioned them as pioneers in the banking sector’s adoption of graph technology.
Essentials of Automations: The Art of Triggers and Actions in FMESafe Software
In this second installment of our Essentials of Automations webinar series, we’ll explore the landscape of triggers and actions, guiding you through the nuances of authoring and adapting workspaces for seamless automations. Gain an understanding of the full spectrum of triggers and actions available in FME, empowering you to enhance your workspaces for efficient automation.
We’ll kick things off by showcasing the most commonly used event-based triggers, introducing you to various automation workflows like manual triggers, schedules, directory watchers, and more. Plus, see how these elements play out in real scenarios.
Whether you’re tweaking your current setup or building from the ground up, this session will arm you with the tools and insights needed to transform your FME usage into a powerhouse of productivity. Join us to discover effective strategies that simplify complex processes, enhancing your productivity and transforming your data management practices with FME. Let’s turn complexity into clarity and make your workspaces work wonders!
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionAggregage
Join Maher Hanafi, VP of Engineering at Betterworks, in this new session where he'll share a practical framework to transform Gen AI prototypes into impactful products! He'll delve into the complexities of data collection and management, model selection and optimization, and ensuring security, scalability, and responsible use.
Communications Mining Series - Zero to Hero - Session 1DianaGray10
This session provides introduction to UiPath Communication Mining, importance and platform overview. You will acquire a good understand of the phases in Communication Mining as we go over the platform with you. Topics covered:
• Communication Mining Overview
• Why is it important?
• How can it help today’s business and the benefits
• Phases in Communication Mining
• Demo on Platform overview
• Q/A
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
8. Principle of candidate antigen and epitope selection by ELISA using human sera Patients (group A) Patients (group B) Healthy individuals Peptide screening with human Abs (ELISA) Gene accession number: ORF# X ORF X -01 ORF X -02 ORF X -03 ORF X -04 ORF X -05 ORF X -06 ORF X -07 ORF X -08 An example of the “candidate antigen” selected by genomic library screening Epitope – the antibody binding site on an antigen (5-30 aa)
23. OPK assay using human granulocytes (HL60) Opsonization (40min, RT) Human HL60 cell line differentiated into granulocytes Incubation 20min at 37C = uptake of bacteria Continue incubation for additional time points at 37C to determine intracellular killing rate (30min, 1hr, 2hr and 3hr) Lysis after 20min incubation with HL60: plated out released bacteria to determine the uptake Lysis and plating of the released bacteria STEP 1: STEP 2: S.pyogenes + + Complement (4% baby rabbit serum) ASSAY SETUP WITH RABBIT COMPLEMENT Antibiotic killing 40min at 4C ( 2% or 20 µg/ml Pen/Streptomycine) Antibodies
24.
25. OPK assay using mouse macrophages TESTING UPTAKE AND KILLING KINETICS PAGE Non-specific (pre-existing) Ab S.pyogenes-specific Ab S.pyogenes + Mouse antibodies OPSONIZATION INCUBATION 1hr , 37C =uptake of bacteria Continued incubation for additional 6hr at 37C to determine intracellular killing Lysis and plating released bacteria. UPTAKE: KILLING: Antibiotic killing of extracellular bacteria 40min at 4C (Pen/Streptomycine) Lysis after 1hr incubation with MFs: plating out released bacteria to determine the uptake.
26.
27. OPK assay using mouse macrophages TESTING EFFECT OF HUMAN PLASMA ON UPTAKE AND KILLING OF S. PYOGENES PAGE Non-specific (pre-existing) Ab S.pyogenes-specific Ab Pre-incubation with human plasma Without human plasma + Mouse antibodies OPSONIZATION *binding of both specific and non-specific Abs S.pyogenes Non-immune human plasma + Y Y Bacteria coated with human plasma proteins OPSONIZATION Mouse Abs bound in the correct orientation S.pyogenes + Mouse antibodies UPTAKE KILLING